Drug Type siRNA |
Synonyms Zodasiran Sodium + [1] |
Target |
Mechanism ANGPTL3 inhibitors(Angiopoietin like 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Start Date22 Apr 2022 |
Sponsor / Collaborator |
Start Date28 Jun 2021 |
Sponsor / Collaborator |
Start Date07 Jan 2019 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Homozygous familial hypercholesterolemia | Phase 2 | AU | 22 Apr 2022 | |
Homozygous familial hypercholesterolemia | Phase 2 | ZA | 22 Apr 2022 | |
Homozygous familial hypercholesterolemia | Phase 2 | US | 22 Apr 2022 | |
Homozygous familial hypercholesterolemia | Phase 2 | CA | 22 Apr 2022 | |
Dyslipidemias | Phase 2 | AU | 28 Jun 2021 | |
Dyslipidemias | Phase 2 | US | 28 Jun 2021 | |
Hypertriglyceridemia | Phase 2 | AU | 07 Jan 2019 | |
Hypertriglyceridemia | Phase 2 | NZ | 07 Jan 2019 | |
Dyslipidemias | Phase 1 | NZ | 28 Jun 2021 | |
Dyslipidemias | Phase 1 | CA | 28 Jun 2021 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 204 | Placebo+ARO-ANG3 (Placebo) | cegapenyqi(xvqoekcfyx) = eoeaufeavp ktwdcggxxp (sqaojmbfou, lbggcuqtwz - dqiqnpuqxl) View more | - | 16 Jan 2024 | ||
(ARO-ANG3 50 mg) | cegapenyqi(xvqoekcfyx) = akhyauhyut ktwdcggxxp (sqaojmbfou, xqdzflfvio - pgavqzfmkf) View more |